296 related articles for article (PubMed ID: 35390293)
21. Mucormycosis: The hidden and forgotten disease.
Darwish RM; AlMasri M; Al-Masri MM
J Appl Microbiol; 2022 Jun; 132(6):4042-4057. PubMed ID: 35156271
[TBL] [Abstract][Full Text] [Related]
22. Expert consensus statements for the management of COVID-19-related acute respiratory failure using a Delphi method.
Nasa P; Azoulay E; Khanna AK; Jain R; Gupta S; Javeri Y; Juneja D; Rangappa P; Sundararajan K; Alhazzani W; Antonelli M; Arabi YM; Bakker J; Brochard LJ; Deane AM; Du B; Einav S; Esteban A; Gajic O; Galvagno SM; Guérin C; Jaber S; Khilnani GC; Koh Y; Lascarrou JB; Machado FR; Malbrain MLNG; Mancebo J; McCurdy MT; McGrath BA; Mehta S; Mekontso-Dessap A; Mer M; Nurok M; Park PK; Pelosi P; Peter JV; Phua J; Pilcher DV; Piquilloud L; Schellongowski P; Schultz MJ; Shankar-Hari M; Singh S; Sorbello M; Tiruvoipati R; Udy AA; Welte T; Myatra SN
Crit Care; 2021 Mar; 25(1):106. PubMed ID: 33726819
[TBL] [Abstract][Full Text] [Related]
23. Pulmonary mucormycosis diagnosed by ultrasound guided percutaneous biopsy: A case series.
Yadav RK; Karmakar S; Raouf Wani A; V V
Indian J Tuberc; 2024 Apr; 71(2):225-231. PubMed ID: 38589128
[TBL] [Abstract][Full Text] [Related]
24. Adjunctive use of saturated solution of potassium iodide (SSKI) with liposomal amphotericin B (L-AMB) in mucormycosis achieves favorable response, shortened dose and duration of amphotericin: A retrospective study from a COVID-19 tertiary care center.
Mrig S; Sardana K; Arora P; Narula V; Arora S; Kapoor A; Baruah RR; Sen P; Agarwal S; Sachdeva S; Dewan A; Panesar S
Am J Otolaryngol; 2022; 43(3):103465. PubMed ID: 35429848
[TBL] [Abstract][Full Text] [Related]
25. Multicenter Epidemiologic Study of Coronavirus Disease-Associated Mucormycosis, India.
Patel A; Agarwal R; Rudramurthy SM; Shevkani M; Xess I; Sharma R; Savio J; Sethuraman N; Madan S; Shastri P; Thangaraju D; Marak R; Tadepalli K; Savaj P; Sunavala A; Gupta N; Singhal T; Muthu V; Chakrabarti A;
Emerg Infect Dis; 2021 Sep; 27(9):2349-2359. PubMed ID: 34087089
[TBL] [Abstract][Full Text] [Related]
26. Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis.
Marty FM; Ostrosky-Zeichner L; Cornely OA; Mullane KM; Perfect JR; Thompson GR; Alangaden GJ; Brown JM; Fredricks DN; Heinz WJ; Herbrecht R; Klimko N; Klyasova G; Maertens JA; Melinkeri SR; Oren I; Pappas PG; Ráčil Z; Rahav G; Santos R; Schwartz S; Vehreschild JJ; Young JH; Chetchotisakd P; Jaruratanasirikul S; Kanj SS; Engelhardt M; Kaufhold A; Ito M; Lee M; Sasse C; Maher RM; Zeiher B; Vehreschild MJGT;
Lancet Infect Dis; 2016 Jul; 16(7):828-837. PubMed ID: 26969258
[TBL] [Abstract][Full Text] [Related]
27. Spotlight on isavuconazole in the treatment of invasive aspergillosis and mucormycosis: design, development, and place in therapy.
Jenks JD; Salzer HJ; Prattes J; Krause R; Buchheidt D; Hoenigl M
Drug Des Devel Ther; 2018; 12():1033-1044. PubMed ID: 29750016
[TBL] [Abstract][Full Text] [Related]
28. ESCMID and ECMM joint clinical guidelines for the diagnosis and management of mucormycosis 2013.
Cornely OA; Arikan-Akdagli S; Dannaoui E; Groll AH; Lagrou K; Chakrabarti A; Lanternier F; Pagano L; Skiada A; Akova M; Arendrup MC; Boekhout T; Chowdhary A; Cuenca-Estrella M; Freiberger T; Guinea J; Guarro J; de Hoog S; Hope W; Johnson E; Kathuria S; Lackner M; Lass-Flörl C; Lortholary O; Meis JF; Meletiadis J; Muñoz P; Richardson M; Roilides E; Tortorano AM; Ullmann AJ; van Diepeningen A; Verweij P; Petrikkos G; ;
Clin Microbiol Infect; 2014 Apr; 20 Suppl 3():5-26. PubMed ID: 24479848
[TBL] [Abstract][Full Text] [Related]
29. Mucormycosis: New Developments into a Persistently Devastating Infection.
Danion F; Aguilar C; Catherinot E; Alanio A; DeWolf S; Lortholary O; Lanternier F
Semin Respir Crit Care Med; 2015 Oct; 36(5):692-705. PubMed ID: 26398536
[TBL] [Abstract][Full Text] [Related]
30. Surgical Challenges in the Management of Post COVID-19 Midface Mucormycosis (PCoMM): An Institutional Protocol.
Tomar K; Roy ID; Natarajan MR; Singh AK; Ramanujam V
J Craniofac Surg; 2023 Jan-Feb 01; 34(1):e46-e52. PubMed ID: 36008879
[TBL] [Abstract][Full Text] [Related]
31. Rhino-orbital mucormycosis following COVID-19 in previously non-diabetic, immunocompetent patients.
Nair AG; Adulkar NG; D'Cunha L; Rao PR; Bradoo RA; Bapaye MM; Kothari A; Dave TV; Shinde CA
Orbit; 2021 Dec; 40(6):499-504. PubMed ID: 34338124
[TBL] [Abstract][Full Text] [Related]
32. A Delphi Consensus Approach for the Management of Chronic Pain during and after the COVID-19 Era.
Cascella M; Miceli L; Cutugno F; Di Lorenzo G; Morabito A; Oriente A; Massazza G; Magni A; Marinangeli F; Cuomo A; On Behalf Of The Delphi Panel
Int J Environ Res Public Health; 2021 Dec; 18(24):. PubMed ID: 34948983
[TBL] [Abstract][Full Text] [Related]
33. Disseminated Mucormycosis With Cerebral Involvement Owing to Rhizopus Microsporus in a Kidney Recipient Treated With Combined Liposomal Amphotericin B and Posaconazole Therapy.
Ville S; Talarmin JP; Gaultier-Lintia A; Bouquié R; Sagan C; Le Pape P; Giral M; Morio F
Exp Clin Transplant; 2016 Feb; 14(1):96-9. PubMed ID: 25275881
[TBL] [Abstract][Full Text] [Related]
34. Mucormycosis, The Deadly New Worry to COVID-19 Pandemic.
Kamrul-Hasan AB; Selim S
Mymensingh Med J; 2021 Jul; 30(3):874-880. PubMed ID: 34226483
[TBL] [Abstract][Full Text] [Related]
35. Mucormycosis and aspergillosis: The deadly duo in COVID-19-a case report.
Mohanty B; Ansari Z; Prasad A; Gupta M; Kumar A
J Family Med Prim Care; 2022 Oct; 11(10):6529-6532. PubMed ID: 36618238
[TBL] [Abstract][Full Text] [Related]
36. Cost-effectiveness analysis of isavuconazole versus voriconazole for the treatment of patients with possible invasive aspergillosis in Sweden.
Floros L; Kuessner D; Posthumus J; Bagshaw E; Sjölin J
BMC Infect Dis; 2019 Feb; 19(1):134. PubMed ID: 30744563
[TBL] [Abstract][Full Text] [Related]
37. [Mucormycosis: therapeutic news].
Pilmis B; Lanternier F; Lortholary O
Med Sci (Paris); 2013 Mar; 29 Spec No 1():25-30. PubMed ID: 23510522
[TBL] [Abstract][Full Text] [Related]
38. Results from a national survey on COVID-19-associated mucormycosis in Germany: 13 patients from six tertiary hospitals.
Seidel D; Simon M; Sprute R; Lubnow M; Evert K; Speer C; Seeßle J; Khatamzas E; Merle U; Behrens C; Blau IW; Enghard P; Haas CS; Steinmann J; Kurzai O; Cornely OA
Mycoses; 2022 Jan; 65(1):103-109. PubMed ID: 34655486
[TBL] [Abstract][Full Text] [Related]
39. Treatment of mucormycosis in transplant patients: role of surgery and of old and new antifungal agents.
Chitasombat MN; Kontoyiannis DP
Curr Opin Infect Dis; 2016 Aug; 29(4):340-5. PubMed ID: 27191199
[TBL] [Abstract][Full Text] [Related]
40. [Pulmonary mucormycosis: report of 5 cases and review of 46 cases reported in China].
Yang YM; Fang BM; Xu XM; Fang F; Pan MM; Zhong XF; Sun TY
Zhonghua Jie He He Hu Xi Za Zhi; 2013 Aug; 36(8):572-6. PubMed ID: 24252732
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
